Humira approved for use in moderate Crohn's disease

The licensed indications for Humira (adalimumab) have been extended to include the treatment of adults with moderately active Crohn's disease, in addition to use in severe disease.

NICE guidance recommending adalimumab for use in severely active Crohn’s disease has been in place since 2010 | SCIENCE PHOTO LIBRARY
NICE guidance recommending adalimumab for use in severely active Crohn’s disease has been in place since 2010 | SCIENCE PHOTO LIBRARY

The TNF-alpha inhibitor should be used only when the response to conventional therapy, including a corticosteroid and/or an immunosuppressant, is inadequate or when such therapies are not tolerated or are contraindicated. 

View Humira drug record

Further information: AbbVie


Follow MIMS on Twitter


Read these next

In Depth | Entyvio: gut-selective immunosuppressant for inflammatory bowel disease

In Depth | Entyvio: gut-selective immunosuppressant for inflammatory bowel disease

Takeda has launched Entyvio (vedolizumab) for the treatment...

TNF inhibitors: prescribers reminded of tuberculosis risk

TNF inhibitors: prescribers reminded of tuberculosis risk

The MHRA has issued a reminder to prescribers regarding...

Humira licensed for paediatric Crohn's

Humira licensed for paediatric Crohn's

The licensed indications for Humira (adalimumab) have...

Further licence extension for adalimumab in arthritis

Further licence extension for adalimumab in arthritis

Humira is the first biologic specifically licensed...

Humira: new treatment option for ulcerative colitis

Humira: new treatment option for ulcerative colitis

Humira (adalimumab) can now be prescribed for the treatment...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.